Cardium Therapeutics, Inc. (CXM) Continues with Growth Strategy Implementation
When Cardium Therapeutics recently released their 2012 financial results, reflecting the company’s extensive investment required for the important introduction of Excellagen and nutraceutical initiatives, and the initiation of their Generx ASPIRE clinical study, the standout feature of the report was the extensive list of achievements put in place to drive Cardium’s long-term growth strategy.
Cardium is actively advancing its Generx DNA-based angiogenic growth factor therapeutic, a one-of-a-kind treatment for heart blood flow problems which, unlike other treatments, actually stimulates blood vessel growth in the heart. Closer to market is the company’s Excellagen wound treatment product, which will eventually help support the Generx program. Cardium’s nutraceutical initiatives, centered around the company’s recent acquisition of To Go Brands, are already providing the significant source of income.
Relating to Generx, the report indicated that Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods. The company made a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum held in Washington, DC, and has also received a favorable patent decision in Europe, along with a successful resolution of a competition over rights to key methods for the application of cardiovascular gene therapy in the treatment of coronary heart disease.
The report also highlighted a number of accomplishments related to Cardium’s continuing progress in the commercialization of its FDA-cleared Excellagen product, a wound treatment gel that has been shown to significantly improve healing for many types of wounds. Cardium has now entered into a logistics and cold chain services agreement with Smith Medical Partners, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations.
Separately, Cardium has now established a strong foothold in the revenue-generating nutraceutical industry, through its successful acquisition of To Go Brands nutraceutical supplement platform, with over 25 products being developed and sold through established regional and national food, drug, and mass channel retailers at over 10,000 retail locations. In addition, the company has developed a new in-house partner-enabled product opportunity, LifeAgain, a set of algorithms and programs to support specialized survivable risk life insurance underwritings for cancer patients and patients with chronic medical diseases.
For additional information, visit www.CardiumTHX.com
Please read full disclaimers at http://disclaimer.missionir.com